These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cost analysis of paroxetine versus imipramine in major depression. Bentkover JD; Feighner JP Pharmacoeconomics; 1995 Sep; 8(3):223-32. PubMed ID: 10155618 [TBL] [Abstract][Full Text] [Related]
5. Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada. Lapierre Y; Bentkover J; Schainbaum S; Manners S Can J Psychiatry; 1995 Sep; 40(7):370-7. PubMed ID: 8548716 [TBL] [Abstract][Full Text] [Related]
6. Something rotten in the state of clinical and economic evaluations? Freemantle N; Maynard A Health Econ; 1994; 3(2):63-7. PubMed ID: 7880237 [No Abstract] [Full Text] [Related]
8. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Jönsson B; Bebbington PE Br J Psychiatry; 1994 May; 164(5):665-73. PubMed ID: 7921718 [TBL] [Abstract][Full Text] [Related]
9. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Feighner JP; Boyer WF J Clin Psychiatry; 1992 Feb; 53 Suppl():44-7. PubMed ID: 1531824 [TBL] [Abstract][Full Text] [Related]
10. Paroxetine. A pharmacoeconomic evaluation of its use in depression. Wilde MI; Whittington R Pharmacoeconomics; 1995 Jul; 8(1):62-81. PubMed ID: 10155603 [TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic issues in the treatment of depression. Cohen LJ Formulary; 1995 Sep; 30 Suppl 1():S20-5. PubMed ID: 10151739 [TBL] [Abstract][Full Text] [Related]
12. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. Fabre LF J Clin Psychiatry; 1992 Feb; 53 Suppl():40-3. PubMed ID: 1531823 [TBL] [Abstract][Full Text] [Related]
13. A double-blind comparison of paroxetine, imipramine, and placebo in major depression. Shrivastava RK; Shrivastava SH; Overweg N; Blumhardt CL J Clin Psychiatry; 1992 Feb; 53 Suppl():48-51. PubMed ID: 1531825 [TBL] [Abstract][Full Text] [Related]
14. Economic analysis of treating depression with nefazodone v. imipramine. Montgomery SA; Brown RE; Clark M Br J Psychiatry; 1996 Jun; 168(6):768-71. PubMed ID: 8773822 [TBL] [Abstract][Full Text] [Related]
15. Paroxetine in major depression: a double-blind trial with imipramine and placebo. Cohn JB; Wilcox CS J Clin Psychiatry; 1992 Feb; 53 Suppl():52-6. PubMed ID: 1531826 [TBL] [Abstract][Full Text] [Related]
16. A comparison of paroxetine, imipramine and placebo in depressed out-patients. Dunbar GC; Cohn JB; Fabre LF; Feighner JP; Fieve RR; Mendels J; Shrivastava RK Br J Psychiatry; 1991 Sep; 159():394-8. PubMed ID: 1835664 [TBL] [Abstract][Full Text] [Related]
17. A placebo- and imipramine-controlled study of paroxetine. Cohn JB; Crowder JE; Wilcox CS; Ryan PJ Psychopharmacol Bull; 1990; 26(2):185-9. PubMed ID: 2146697 [TBL] [Abstract][Full Text] [Related]
18. Modelling the cost effectiveness of antidepressant treatment in primary care. Revicki DA; Brown RE; Palmer W; Bakish D; Rosser WW; Anton SF; Feeny D Pharmacoeconomics; 1995 Dec; 8(6):524-40. PubMed ID: 10160081 [TBL] [Abstract][Full Text] [Related]
19. The short- and long-term efficacy of paroxetine HCl: A. Data from a 6-week double-blind parallel design trial vs. imipramine and placebo. Peselow ED; Filippi AM; Goodnick P; Barouche F; Fieve RR Psychopharmacol Bull; 1989; 25(2):267-71. PubMed ID: 2532373 [No Abstract] [Full Text] [Related]
20. The short- and long-term efficacy of paroxetine HCl: B. Data from a double-blind crossover study and from a year-long term trial vs. imipramine and placebo. Peselow ED; Filippi AM; Goodnick P; Barouche F; Fieve RR Psychopharmacol Bull; 1989; 25(2):272-6. PubMed ID: 2532374 [No Abstract] [Full Text] [Related] [Next] [New Search]